<img alt="" src="https://secure.agile-company-365.com/781893.png" style="display:none;">
Skip to content

Investors Centre

Goal:  Provide a concise overview of Trajan and its influence within the community

Audience value: Introduces users and gives a brief understanding into what Trajan as an investor entails and it’s impact.

Quick Links


         Board of Directors          Announcements and Reports          Shareholder Information          Corporate Governance

A message from Stephen and John

We started our journey to make a difference. To develop analytical and scientific products and services that would enable critical improvement in the analytical workflow to benefit our customers and partners.

It was also an aspiration that we knew could lead to a profound impact on human well-being enabled by the delivery of precision products that protect the sample integrity and minimise result variation, leading to more informed decisions and treatments.

We welcome you as an investor and invite you to take a tour of the Trajan facilities around the world to meet some of our incredible team who, like us, are supporting science that benefits people
Screen_Shot_2021_05_10_at_9_06_33_pm_10a8447591_cbe501d909-nobackground
Stephen Tomisich (CEO & Founder) & John Eales (Chair)

Strength in solutions

 

Goal: Give an overview in why you should invest with Trajan. Highlight key reasons to
invest in Trajan by showcasing the company’s performance, growth, and strategic
initiatives, demonstrating its potential for long-term value.

Audience value: Provides investors with a clear understanding of the benefits and
opportunities that come with investing in Trajan, emphasising financial growth,
innovation, and the company's positive impact on the scientific and medical fields.

Strong customer relationships
Strong customer relationshipsLong-term relationships with global ‘blue-chip’ customers including OEMs, pharmaceutical companies and contract research organisations. 
Market leading innovator
Market leading innovatorStrong technical expertise and know-how of the manufacturing of precision analytical instruments and components. Portfolio of innovative technologies and devices to support the trend towards decentralised, personalised data-based healthcare. 
High quality and experienced management team
High quality and experienced management teamGlobal management team led by founders, assembled to provide the human capital platform required to execute on growth strategy. 
Global infrastructure
Global infrastructureManufacturing and distribution operations, systems and certifications designed for customer proximity with 5 sites across 3 continents. 
Ready to scale
Ready to scaleDeep technology commercialisation pipeline and globally identified acquisition targets provide significant upside potential to the existing and strong underlying consumable and components business. 
Strong track record
Strong track record7 complementary acquisitions completed pre listing, all self funded through continued high financial performance. 

Latest news and events

Goal: Present the latest investor news and events to keep stakeholders informed
about Trajan’s updates, achievements, and industry participation.

Audience value: Audiences will view Trajan as a transparent and informative
company, staying current with industry news and developments, which strengthens
trust and engagement with investors.

Latest announcements and reports

Trajan has a broad network of distributors worldwide. You can choose a supplier delivering to your location via our global distribution network.

Loading reports...

Financial Scorecard

 

 

FY 2025
FINANCIAL RESULTS
 

 

 Group Revenue 

 $166.5M 

 UP 7.4% (PCP $155.0M) 

 nEBITDA 

 $15.5M 

 UP 26.2% (PCP $12.3M) 

 Proforma Gross Margin 

 39.8% 

 DOWN 1.3 POINTS (PCP 41.1%) 

 

 

COMPONENTS & CONSUMABLES:

Includes parts, supplies, components, and consumable products across the Group.

 
Revenue

$102.7M

(PCP $96.2M)
nEBITDA

$34.9M

(PCP $32.3M)
Proforma Gross Margin

41.6%

(PCP 41.1%)

 

 

CAPITAL EQUIPMENT:

Includes robotic workflow automation systems, online and laboratory instruments, and parts and services related to them.

 
Revenue

$58.6M

(PCP $53.9M)
nEBITDA

$9.7M

(PCP $9.7M)
Proforma Gross Margin

35.1%

(PCP 40.2%)

 

 

 

DISRUPTIVE TECHNOLOGIES:

 

Includes products and services related to micro-sampling, devices, services, and other related investments as well as miniaturised, portable instrumentation, i.e. Versiti.

 
Revenue

$5.1M

(PCP $4.9M)
nEBITDA

($1.5M)

(PCP $(4.9M))
Proforma Gross Margin

57.0%

(PCP 52.7%)

Sign up for email alerts

Stay updated with ASX announcements and quarterly newsletters

* indicates required

Investor Contact

If you can’t find what you’re looking for on our website we’re happy to answer any questions about our company and products. Please connect with us on investorrelations@trajanscimed.com

Sign up for email alerts

Stay updated with ASX announcements and quarterly newsletters

* indicates required